Table 1 The functions of m6A methyltransferases in drug and radiotherapy resistance
From: N6-methyladenosine methyltransferases: functions, regulation, and clinical potential
| Therapy type | Drug name | Cancer | Regulator | Regulation | Target | References |
|---|---|---|---|---|---|---|
| Chemo-therapy | Cisplatin | Seminoma | METTL3 | PR | TFAP2C | [92] |
| Gastric cancer | METTL3 | PR | ARHGAP5 | [93] | ||
| NSCLC | METTL3 | ES | FSP1 | [94] | ||
| NKTCL | WTAP | PR | DUSP6 | [95] | ||
| Nasopharyngeal carcinoma | METTL3 | PR | TRIM11 | [43] | ||
| Oxaliplatin | Colorectal cancer | METTL3 | PR | P53/Sec62 | [96] | |
| Taxol | Breast cancer | METTL3 | PR | ERRγ | [98] | |
| Doxorubicin (adriamycin) | Breast cancer | METTL3 | PR | pri-microRNA-221-3p | [100] | |
| Anthracycline | Breast cancer | METTL3 | PR | ABCB1 | [98] | |
| Targeted therapy | Everolimus | Gastric tumors | METTL3 | ES | pri-miR-17–92 | [53] |
| Crizotinib | NSCLC | METTL3/WTAP | PR | c-MET | [108] | |
| Gefitinib | NSCLC | METTL3 | PR | METTL3-mediated Autophagy | [110] | |
| Lung Adenocarcinoma | METTL3 | PR | c-MET | [111] | ||
| Sorafenib | HCC | METTL14 | PR | HNF3γ | [112] | |
| HCC | METTL3/14 | PR | circRNA-SORE | [42] | ||
| HCC | METTL3 | ES | FOXO3 | [74] | ||
| Immuno therapy | Anti-PD-1 | Melanoma | METTL3 (macrophages) | PR | SPRED2 | [57] |
| Colorectal carcinoma/Melanoma | METTL3/14 | PR | Stat1/Irf1 | [117] | ||
| Radio-therapy | γ-irradiation | Glioblastoma | METTL3 | PR | SOX2 | [76] |
| X-ray Irradiation | Hypopharyngeal Squamous cell carcinoma | METTL3 | PR | circCUX1 | [119] |